Member Info for chester18

The RNS is confirming that these clinical cancer experts have all signed up to be the CAB for the Registration Trail that ‘is’ happening in 2025.

There are no if’s, but’s or maybe’s, the data so far collated is well above 70% ORR so Scancell can be confident that the final ORR numbers are going to be so good that they are already telling us.

The RNS is not cryptic it’s just a massive heads-up.

35 trades on Aquis and your trade is there .

👍👍

Scancell is obviously being talked about and sentiment has now changed towards the positive. This current rise is happening because a company owning two successful platforms in the emerging field of cancer vaccines, should not be missed.

We are still in a speculation period but with data due in the coming months that could transform from ‘What If’ into ‘How Big’ can this become.

For me iSCIB+ is the key to Scancell having the opportunity to grow into a very large multi £billion company. The perfect scenario is that a substantial Pharma / Biotech company partners Scancell in the SCOPE Registration Phase 2/3 Trial.

The monetary value of such a partnership will drive iSCIB+ to commercialisation and provide the necessary financial resources to allow Modi1 + CPIs, Modi2 and SC134 through clinical trials and beyond.

We are right at the point where such dreams can become reality.

Thanks GF123

We know that the data is building up and news cannot to far away, so this week would be fine with me.

👊👊

Hi C11

I thought it was worth sketching out. Obviously we don’t know exactly how the dosing is going but we can be sure that one or maybe two patients have reach there scans and Scancell will have some iSCIB+ data.

I’m trying to keep my feet on the ground and I’ve told myself to expect the big news items November / December. Anything earlier is going to be a bonus.

We are definitely getting close to finding out if the data is just good, very good or awesome. 🤞

Drac if I may answer that question.

1st Patient Dosed 26th March 2024

1st Patient 13 Week Scan 25th June.

Probable that they would wait to dose a second patient for 2/4 weeks as part of the safety protocols. This is where we make best guesses.

2nd Patient Dosed end of April followed by a full roll out. This now depends on how many patients per month enrol and pass the vetting process to be dosed but I’m going to take something Sath said about 10 patients enrolled in one month to estimate a minimum of 5 and a maximum of 8 patients per month.

Therefore : Min. Max.

Scans : End June 1 - 1

End July 2 - 4

End Aug. 7 - 12

End Sept. 12 - 20

End Oct. 17 - 28

If recruitment, enrolment and acceptance rates are more like 10 per month the 27 Scanned patients could be a month earlier but that would be at full steam.

Also it all depends on the ORR it is very unlikely that we get 27 out of 27.

In summary the magic number of 27 positive responders out of 34 could happen by the End of October or early in November.

Just in time for a blockbuster AGM.

The shambles of Neil Woodford’s future investment funds left a really bad impression of UK Biotech’s ability to become commercially profitable and ensured that UK investors steered well clear.

He took hard earned pensions and then manipulated the share price of his stock picks by having two or three funds buy the stock, inflating their values.

Most had good prospects but needed time to develop their particular business.

I had experience with a stem cell company called Reneuron, where the Woodford funds ploughed £70m into the company on the basis that this new technology could be fast tracked with cash. As we all know it takes dedication from the scientists sometimes over decades to find the right set of circumstances for embryonic technologies establish a pathway that works commercially.

That particular debacle did the UK Biotech and for that matter, the AIM Market no favours whatsoever.

I’m just waiting for one of them to raise the old issue of ‘this going to 4x 5p’ you know, that old chestnut 🤔

🤣🤣

Positive Data is what will determine if Scancell have valuable breakthrough cancer treatments.

Positive Data from enough patients to show statistically that the platforms can be effective and rolled out worldwide. That will create the right conditions to encourage large pharma companies to compete to own that technology.

As investors we await the ‘potential’ results to transform into ‘confirmed positive’ results.

That data is building every single day and will be reported as soon as it reaches a critical mass that is verified and approved to be released in an RNS.

All the external conditions are in place for a very considerable bid to land on LD’s desk when there is indisputable proof that the science is sound and the patients on our trials are experiencing life changing outcomes.

It’s all about the quality of the data.

It has been suggested many times that it’s Calculus Capital investments.

They own or owned many millions of Scancell shares and it’s been said that they need to sell shares across their instruments to pay for withdrawals from their fund.

This is hear say but they do fit the MO.

It does feel like we a poised for an upturn in the share price but it hinges on the new found positive sentiment overcoming a relentless seller.

I honestly think that if a positive piece of news lands very soon, it will massively bolster this change in sentiment towards the value of Scancell’s Market Capitalisation and help solidify these gains.

Early news from iSCIB+ or 1st patient dosed in the Modi1 + doubled checkpoint would do the job. Anything solid and positive to add to the excellent progress already made by Scancell.

Violindog……

Any chance you could accidentally buy a few more shares, even if it’s just 190 …..

🤣👍

Thanks emptyend

The recorded data for SCIB1 + 2CPI’s should now be from a minimum of approx 18 patients, hopefully more. If it is still reaching the high 70’s ORR or higher, the Scancell team will be content that they are well on their way to achieving the 27 out of 43 that was stated as the threshold number to confirm a Registration Trial can happen.

They also have the data from at least one patient from the iSCIB+ cohort so they will know if the improvement's in the Avidity have worked without being overly toxic.

The next big news item for me will be when they report how iSCIB+ has performed in the early patients. If the whole cohort passes with flying colours then I would hope the UK government will take note and put some effort into supporting and promoting Scancell as a beacon of what can be achieved by our home grown biotech companies.

Talk of listing on the NasDaq is partly posturing and partly having some clear routes to more development money.

Looking at the Scope trial in isolation, if the data for iSCIB+ shows continued low or no toxicity and the ORR is above 70% across this now 100% non selective cohort of patients, it will absolutely be chosen for the Registration Trial.

That trial is 100 patients Phase2 and 300 patients in Phase3 over 18 months.

Submission and Approval could mean that it’s up and running by April / May 2025 and completion by Late 2026.

We don’t currently have £60m to £100m of funds to do such a huge trial, so what are the possible routes to that amount of funding. Let’s assume great data in the next 4 months translates to an SP around 25p.

A ) A new fund raise and open offer at 20p issuing around 400,0000,0000 new shares.

B ) A very quick transfer to List on the Nasdaq is possible and probably using the same volume of dilution to achieve the required funds.

C ) Partner up with a Pharma or Biotech big enough to fund that Registration Trial meaning that Scancell has to give away the vast majority of future revenue. That is countered by them taking on the lions share of the Risk and Scancell having a stronger balance sheet.

D ) The whole Immunobody platform is sold to the highest bidder.

Having all these positions covered and the CLN’s kicked out of the way to 2027 means that any serious approaches will need to have big numbers attached or Scancell shrug their shoulders and politely say we’re going it alone.

It’s all about the data but everything that is happening now tells us that the data is well above just average.

Miavoce I can’t find a website that states who is on Redmiles Board so my saying he is part of their board is based solely on his position in the company. I presumed that a CEO automatically had a seat .

@ emptyend

Totally agree with your thoughts. Scancell know the result of our 1st iSCIB+ patients 1st scan. If the scan results were a dud or well below that of SCIB1 we would be told and Redmile would not be chomping at the bit to have a place on the board.

The most practical arrangement for the SCOPE Registration Trial would be to partner up with the owner of the two checkpoints. An up front cash figure plus them taking a long term position by buying a quantity of shares on the open market.

I have seen that happen man the times.

As you say choosing the right option is key.

Happy Birthday TF. 🥳

This is where I saw Dr Florian’s position in the Redmile Group :

Florian Reinaud MD General Information

Biography

Dr. Florian Reinaud serves as a Board Member at OMNI Life Science. He serves as Managing Director at Redmile Group. He serves as a Board Member at Sensome and Sensorion.

Morning Vanvan

Through things that have been said by LD in the past I think there is a very real possibility that Scancell would sell the whole Immunobody platform. I’ve no idea for how much but let’s say £500m as it’s a good round figure.

Scancell would then use that revenue to pursue Modi1 to commercialisation and Modi2 through clinical trials. Also SC134 through clinical trials at the same develop more GlyMab antibodies and targets.

Moditope has the development range to reach a vast range of cancers and could still be advancing into new early clinical trials in 20 years time.

Success at that kind of level would mean thousands of lives saved or given the gift of many more years.

Brilliant JohnnyB1

Excellent detective work 😄😄

The timing of this appointment is very interesting. There must be some relevance as to why Redmile have chosen early July 2024 to take a seat on the board. In addition he is not just ‘their man on the board’ he is a key part of Redmiles own board.

Three parts of our trials that could now have very early data and point clearly towards the success of both Immunobody and Moditope.

1 ) The iSCIB+ first patient will have had their 1st Scan ✔️

2 ) The Modi1 + 2 CPI in Renal Cell Carcinoma could have had their 1st six week scan ( approval 24th May if a patient was ready to be dosed 6 weeks = 5th July ish ) .

3 ) The Neo-Adjuvant cohort, although not complete, there will be 50% of the results where the data is in. ✔️

These three results are extremely important and if all are positive it would be a very strong indicator that these platforms are on their way towards commercial value.

That is when you would expect the large pharmaceutical and biotech companies to start jumping to attention and considering what impact these future technologies could have in the battle against cancers.